# Phase IIa Trial to Determine the Effects of Bardoxolone Methyl on Renal Function in Patients With Diabetic Nephropathy

> **NCT00664027** · PHASE2 · COMPLETED · sponsor: **Biogen** · enrollment: 80 (actual)

## Conditions studied

- Diabetic Nephropathy

## Interventions

- **DRUG:** RTA 402 (Bardoxolone Methyl)

## Key facts

- **NCT ID:** NCT00664027
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04-30
- **Primary completion:** 2009-05-31
- **Final completion:** 2009-05-31
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2025-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00664027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00664027, "Phase IIa Trial to Determine the Effects of Bardoxolone Methyl on Renal Function in Patients With Diabetic Nephropathy". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00664027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*